Robert Pacifici, PhD, is the new chief scientific officer and site director at Sphinx Laboratories, parent company Eli Lilly & Company announced Wednesday.

Pacifici is responsible for the scientific and technical director as well as leadership of the Sphinx operation.

Pacifici previously worked at Xencor as vice president for discovery technologies. He also worked for Amgen, Inc. Pacifici received a B.S. degree in biochemistry at the University of Massachusetts, Amherst, and a doctorate in biochemistry at the University of Southern California. He also is an adjunct professor in molecular pharmacology and toxicology at the University of Southern California.

Robert Armstrong, vice president for discovery chemistry research technology at Lilly, said Pacifici’s work in novel drug compound research and data mining “will have a productive impact on the continued evolution of our lead generation biology.”

Lilly acquired Sphinx in 1994. The labs focus on the screening of possible drug compounds.

“Lilly’s commitment to innovation, backed by its impressive depth and breadth of drug discovery talent, makes this an ideal opportunity,” Pacifica said in a statement.

Lilly has its headquarters in Indianapolis, IN.